RARE DISEASE
Anterior uveitis
Anterior uveitis
Anterior uveitis
Synonyms: Iridocyclitis
Synonyms: Iridocyclitis
Synonyms: Iridocyclitis
Drug discovery
2
drugs
With orphan designations
Overview
Anterior uveitis (AU) is the most common form of uveitis, characterized by inflammation of the iris and ciliary body. Symptoms include ocular pain, photophobia, blurred vision, and conjunctival redness, often presenting acutely but may become chronic or recurrent. Up to 52% of cases have systemic associations, including HLA-B27-related spondyloarthropathies or infections like herpesviruses. Diagnosis requires slit-lamp evaluation for anterior chamber cells/flare and targeted testing for etiology [1][6][11].
Burden
Responsible for 10% of legal blindness in the US, with complications including glaucoma (20%), cataracts, and cystoid macular edema [1][16].
Annual US healthcare costs exceed $241 million, driven by frequent monitoring (5-7 visits per acute episode) and biologics [8][13].
Chronic cases incur 2.5x higher productivity losses vs controls due to visual impairment [16][17].
Therapies
First-line: Aggressive topical corticosteroids (e.g., prednisolone acetate 1% hourly) and cycloplegics (e.g., cyclopentolate) [1][3][11].
Refractory cases: Periocular/intravitreal steroids (triamcinolone) or systemic immunomodulators (methotrexate, adalimumab) [8][13][18].
Infectious causes: Antivirals (acyclovir/valacyclovir for herpesviruses) with concurrent steroids [5][11].
Categories: rare ophthalmic disorders
Research Papers
1,261 drug discovery papers related to Anterior uveitis, with 3 first-in-class and 7 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
1,261 drug discovery papers related to Anterior uveitis, with 3 first-in-class and 7 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-08 | Long-term structural impact and antiviral efficacy of cytomegalovirus anterior uveitis - results from a 10-year ocular inflammation registry.
To evaluate criteria-based long-term structural outcomes and dose-dependent antiviral effects in cytomegalovirus anterior uveitis (CMV AU). From a 10-year ocular inflammation registry comprising 1,404 patients, 79 eyes from 67 patients with PCR-confirmed CMV AU were identified (mean follow-up, 48 ± 38 months). Serial assessments included retinal nerve fiber layer (RNFL) thickness, corneal endothelial cell density (ECCD), and visual field testing. Criteria for manifest glaucoma were defined as RNFL ≤ 75 μm, interocular asymmetry ≥ 15 μm, or visual field defects; manifest ECCD loss as ≥ 20% interocular difference or ECCD ≤ 1500 cells/mm². Initial treatment response (ITR) was defined as IOP normalization and inflammation reduction within 2 weeks. Flare-up rates were compared between high-dose (2% ganciclovir ≥ QID) and low-dose (2% ganciclovir ≤ TID) topical regimens. The mean age was 56.5 ± 15.5 years, and 82.1% had unilateral disease. Median diagnostic delay was 33 months; 20.9% required repeat aqueous taps. ITR was achieved in 87.6%. High-dose topical antivirals reduced flare-ups 2.25-fold vs. low-dose regimens (0.471 vs. 1.058 events/eye-year; relative risk = 0.45). Glaucoma rose from 30.3% to 62.0% and ECCD loss from 27.8% to 57.0% during follow-up. Kaplan-Meier analysis showed a median time of 9 years from symptom-onset to manifest glaucoma. Above-midline KPs were inversely associated with peak IOP on linear regression (p < 0.001). CMV AU poses significant long-term structural risk despite good short-term control. Early criteria-based treatment and high-dose antivirals reduce relapse, while lifelong maintenance is required in eyes with advanced disease.
2026-06-27 | Statin Intensity and the Risk of Noninfectious Uveitis.
To evaluate whether the 5-year risk of incident noninfectious uveitis (NIU) is associated with the intensity of statin therapy in patients with hyperlipidemia. Retrospective, propensity score-matched cohort study. Patients diagnosed with hyperlipidemia within a nationwide federated electronic medical record network (TriNetX). Patients initiating high-, medium-, or low-intensity statin therapy were compared to two mutually exclusive control cohorts: an active comparator control (proton pump inhibitor [PPI] users) and an unexposed control cohort. Patients with prior uveitis or any history of fibrate use were excluded. Each statin intensity cohort underwent 1:1 propensity score matching with both control groups to balance baseline demographics and systemic comorbidities. 5-year hazard ratios (HR) with 95% confidence intervals (CI) for incident overall NIU, anterior uveitis, and posterior/panuveitis. Prior to matching, the study identified 32,434 high-intensity, 16,955 medium-intensity, and 4,843 low-intensity statin users. Following matching, high-intensity statin therapy was associated with a significantly reduced 5-year risk of overall NIU compared to the unexposed control (HR 0.81, 95% CI: 0.69-0.95) with a statistically significant reduction against the active control (HR 0.73, 95% CI: 0.57-0.94). This protective effect was primarily driven by significant reductions in anterior uveitis against both the unexposed control (HR 0.77, 95% CI: 0.65-0.92) and the active control (HR 0.72, 95% CI: 0.55-0.94). Medium-intensity statin therapy yielded a significant risk reduction for overall NIU (HR 0.81, 95% CI: 0.66-0.99) and anterior uveitis (HR 0.84, 95% CI: 0.68-1.03) against the unexposed control but did not reach statistical significance against the active control. Low-intensity statin regimens did not significantly alter the risk of NIU or any anatomical subtype across either comparison group. Negative control outcome analysis demonstrated null associations across all cohorts, supporting the validity of the observed findings. Statin therapy is associated with an intensity-dependent reduction in the 5-year risk of noninfectious uveitis. High-intensity statin regimens confer the most robust and sustained protective benefit, suggesting that higher-potency dosing is necessary to achieve clinically significant modulation of ocular inflammation.
2026-06-25 | Uveitis in spondyloarthritis: clinical patterns and differences between axial and peripheral forms.
The association between uveitis and spondyloarthritis is well established. However, its characterization across the different types of spondyloarthritis remains limited in the literature. Therefore, this study aimed to perform a comparative characterization of uveitis in the various types of spondyloarthritis. Retrospective observational study that included patients with non-infectious uveitis and spondyloarthritis from a multidisciplinary uveitis clinic. A descriptive analysis was performed across the different subtypes of spondyloarthritis, followed by a comparative analysis regrouping patients into axial and peripheral SpA categories. 163 patients with spondyloarthritis-associated uveitis were included, comprising radiographic axial spondyloarthritis (49%), non-radiographic axial spondyloarthritis (21%), spondyloarthritis associated with inflammatory bowel disease (13%), psoriatic arthritis (12%), and peripheral spondyloarthritis (4%). Anterior uveitis (97%), acute relapsing course (79%), and alternating laterality (47.4%) were predominant in the overall sample. When comparing axial versus peripheral forms, significant differences were observed: intermediate, posterior, and panuveitis locations occurred exclusively in the peripheral forms, which also showed higher frequencies of chronic courses (p < 0.001), bilateralism (p < 0.05), and greater use of systemic therapy (p = 0.05). Regarding this treatment to control uveitis, 28.2% of patients required immunomodulatory therapy (more sulfasalazine in axial forms, and methotrexate in peripheral) and 17.8% required biologic therapy. Biologic discontinuation was higher in peripheral forms (p = 0.059). Variables predicting greater need for systemic therapy included chronic course, bilateralism, higher number of annual episodes, younger age of onset, peripheral joint involvement, and presence of vitritis (all p < 0.05). Acute anterior uveitis constitutes the most frequent pattern in all spondyloarthritis types. However, peripheral forms exhibit a higher prevalence of non-anterior, chronic, and bilateral uveitis, and, additionally, appeared to require greater use of immunomodulatory therapy. Key Points • Understanding and distinguishing the ocular inflammatory processes associated with SpA may have important therapeutic and prognostic implications. • Although acute recurrent anterior uveitis was the most frequent patternacross all SpA subtypes, in the peripheral SpA group (pSpA, IBD-SpA, and PsA) a higher prevalence of intermediate, posterior, panuveitis, chronic course, and bilateral uveitis was observed. • The peripheral SpA group (pSpA, IBD-SpA, and PsA) appeared to require greater use of immunomodulatory drugs (csDMARDs or biologics) for control of the ocular condition, suggesting the need for closer monitoring and tailored therapeutic strategies.
2026-07-08 | Long-term structural impact and antiviral efficacy of cytomegalovirus anterior uveitis - results from a 10-year ocular inflammation registry.
To evaluate criteria-based long-term structural outcomes and dose-dependent antiviral effects in cytomegalovirus anterior uveitis (CMV AU). From a 10-year ocular inflammation registry comprising 1,404 patients, 79 eyes from 67 patients with PCR-confirmed CMV AU were identified (mean follow-up, 48 ± 38 months). Serial assessments included retinal nerve fiber layer (RNFL) thickness, corneal endothelial cell density (ECCD), and visual field testing. Criteria for manifest glaucoma were defined as RNFL ≤ 75 μm, interocular asymmetry ≥ 15 μm, or visual field defects; manifest ECCD loss as ≥ 20% interocular difference or ECCD ≤ 1500 cells/mm². Initial treatment response (ITR) was defined as IOP normalization and inflammation reduction within 2 weeks. Flare-up rates were compared between high-dose (2% ganciclovir ≥ QID) and low-dose (2% ganciclovir ≤ TID) topical regimens. The mean age was 56.5 ± 15.5 years, and 82.1% had unilateral disease. Median diagnostic delay was 33 months; 20.9% required repeat aqueous taps. ITR was achieved in 87.6%. High-dose topical antivirals reduced flare-ups 2.25-fold vs. low-dose regimens (0.471 vs. 1.058 events/eye-year; relative risk = 0.45). Glaucoma rose from 30.3% to 62.0% and ECCD loss from 27.8% to 57.0% during follow-up. Kaplan-Meier analysis showed a median time of 9 years from symptom-onset to manifest glaucoma. Above-midline KPs were inversely associated with peak IOP on linear regression (p < 0.001). CMV AU poses significant long-term structural risk despite good short-term control. Early criteria-based treatment and high-dose antivirals reduce relapse, while lifelong maintenance is required in eyes with advanced disease.
2026-06-27 | Statin Intensity and the Risk of Noninfectious Uveitis.
To evaluate whether the 5-year risk of incident noninfectious uveitis (NIU) is associated with the intensity of statin therapy in patients with hyperlipidemia. Retrospective, propensity score-matched cohort study. Patients diagnosed with hyperlipidemia within a nationwide federated electronic medical record network (TriNetX). Patients initiating high-, medium-, or low-intensity statin therapy were compared to two mutually exclusive control cohorts: an active comparator control (proton pump inhibitor [PPI] users) and an unexposed control cohort. Patients with prior uveitis or any history of fibrate use were excluded. Each statin intensity cohort underwent 1:1 propensity score matching with both control groups to balance baseline demographics and systemic comorbidities. 5-year hazard ratios (HR) with 95% confidence intervals (CI) for incident overall NIU, anterior uveitis, and posterior/panuveitis. Prior to matching, the study identified 32,434 high-intensity, 16,955 medium-intensity, and 4,843 low-intensity statin users. Following matching, high-intensity statin therapy was associated with a significantly reduced 5-year risk of overall NIU compared to the unexposed control (HR 0.81, 95% CI: 0.69-0.95) with a statistically significant reduction against the active control (HR 0.73, 95% CI: 0.57-0.94). This protective effect was primarily driven by significant reductions in anterior uveitis against both the unexposed control (HR 0.77, 95% CI: 0.65-0.92) and the active control (HR 0.72, 95% CI: 0.55-0.94). Medium-intensity statin therapy yielded a significant risk reduction for overall NIU (HR 0.81, 95% CI: 0.66-0.99) and anterior uveitis (HR 0.84, 95% CI: 0.68-1.03) against the unexposed control but did not reach statistical significance against the active control. Low-intensity statin regimens did not significantly alter the risk of NIU or any anatomical subtype across either comparison group. Negative control outcome analysis demonstrated null associations across all cohorts, supporting the validity of the observed findings. Statin therapy is associated with an intensity-dependent reduction in the 5-year risk of noninfectious uveitis. High-intensity statin regimens confer the most robust and sustained protective benefit, suggesting that higher-potency dosing is necessary to achieve clinically significant modulation of ocular inflammation.
2026-06-25 | Uveitis in spondyloarthritis: clinical patterns and differences between axial and peripheral forms.
The association between uveitis and spondyloarthritis is well established. However, its characterization across the different types of spondyloarthritis remains limited in the literature. Therefore, this study aimed to perform a comparative characterization of uveitis in the various types of spondyloarthritis. Retrospective observational study that included patients with non-infectious uveitis and spondyloarthritis from a multidisciplinary uveitis clinic. A descriptive analysis was performed across the different subtypes of spondyloarthritis, followed by a comparative analysis regrouping patients into axial and peripheral SpA categories. 163 patients with spondyloarthritis-associated uveitis were included, comprising radiographic axial spondyloarthritis (49%), non-radiographic axial spondyloarthritis (21%), spondyloarthritis associated with inflammatory bowel disease (13%), psoriatic arthritis (12%), and peripheral spondyloarthritis (4%). Anterior uveitis (97%), acute relapsing course (79%), and alternating laterality (47.4%) were predominant in the overall sample. When comparing axial versus peripheral forms, significant differences were observed: intermediate, posterior, and panuveitis locations occurred exclusively in the peripheral forms, which also showed higher frequencies of chronic courses (p < 0.001), bilateralism (p < 0.05), and greater use of systemic therapy (p = 0.05). Regarding this treatment to control uveitis, 28.2% of patients required immunomodulatory therapy (more sulfasalazine in axial forms, and methotrexate in peripheral) and 17.8% required biologic therapy. Biologic discontinuation was higher in peripheral forms (p = 0.059). Variables predicting greater need for systemic therapy included chronic course, bilateralism, higher number of annual episodes, younger age of onset, peripheral joint involvement, and presence of vitritis (all p < 0.05). Acute anterior uveitis constitutes the most frequent pattern in all spondyloarthritis types. However, peripheral forms exhibit a higher prevalence of non-anterior, chronic, and bilateral uveitis, and, additionally, appeared to require greater use of immunomodulatory therapy. Key Points • Understanding and distinguishing the ocular inflammatory processes associated with SpA may have important therapeutic and prognostic implications. • Although acute recurrent anterior uveitis was the most frequent patternacross all SpA subtypes, in the peripheral SpA group (pSpA, IBD-SpA, and PsA) a higher prevalence of intermediate, posterior, panuveitis, chronic course, and bilateral uveitis was observed. • The peripheral SpA group (pSpA, IBD-SpA, and PsA) appeared to require greater use of immunomodulatory drugs (csDMARDs or biologics) for control of the ocular condition, suggesting the need for closer monitoring and tailored therapeutic strategies.
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Anterior uveitis.
2 orphan drug designations for Anterior uveitis.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
E. Coli heat-shock protein 70 with bovine retinal S-antigen | proteins | EMA | 2006-01-24 | — | Biotech Tools SA |
AI-RSA | small molecules | FDA | 1992-10-08 | — | AutoImmune, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.